Oviani Pharma Chem Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 24-10-2024
- Paid Up Capital ₹ 3.00 M
as on 24-10-2024
- Company Age 7 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.21 Cr
as on 24-10-2024
- Revenue 150.51%
(FY 2023)
- Profit 107.45%
(FY 2023)
- Ebitda 47.32%
(FY 2023)
- Net Worth
- Total Assets 132.94%
(FY 2023)
About Oviani Pharma Chem
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 3.00 M.
The company has closed loans amounting to ₹1.21 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Divya Bajaj and Nanak Bajaj serve as directors at the Company.
- CIN/LLPIN
U24304MH2017PTC290096
- Company No.
290096
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Feb 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Oviani Pharma Chem Private Limited offer?
Oviani Pharma Chem Private Limited offers a wide range of products and services, including Antibiotic Tablets & Capsules, Azithromycin Tablets.
Who are the key members and board of directors at Oviani Pharma Chem?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Divya Bajaj  | Whole-Time Director | 02-Feb-2017 | Current |
| Nanak Bajaj | Whole-Time Director | 02-Feb-2017 | Current |
Financial Performance of Oviani Pharma Chem.
Oviani Pharma Chem Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 150.51% increase. The company also saw a substantial improvement in profitability, with a 107.45% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth | |||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oviani Pharma Chem?
In 2023, Oviani Pharma Chem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 19 Nov 2020 | ₹1.44 M | Satisfied |
Others Creation Date: 19 Jun 2020 | ₹1.50 M | Satisfied |
Others Creation Date: 16 May 2017 | ₹2.00 M | Satisfied |
How Many Employees Work at Oviani Pharma Chem?
Unlock and access historical data on people associated with Oviani Pharma Chem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oviani Pharma Chem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oviani Pharma Chem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
